pharmacovigilance.dev

What It Is

Pharmacovigilance.dev is positioned as a pharmacovigilance data mining and intelligent analytics platform for Drug Safety Professionals. Its core format appears to be a BI Dashboard and a prebuilt library of adverse event reports. The product emphasizes helping users save time when generating drug safety reports, with data views and insights organized around branded drugs, generics, adverse events, and companies.

Core Features and Data

Based on the main content, the product offers multi-year and multi-quarter data analysis, with the ability to zoom in and out between high-level and low-level views. It also supports searching, filtering, and aggregating individual reports. The page claims coverage of 800+ Brands & Generics, 1000+ Adverse Events, and 500+ Companies, and provides pre-aggregated reports based on adverse event data mining with quarterly updates. However, the page does not specify the underlying data sources, such as whether the data comes from public regulatory databases, how frequently it is updated, its geographic scope, or the methods used for deduplication and signal detection. For serious drug safety use cases, source validation would still be necessary.

Pricing and Target Users

Pricing is shown as a Demo plan at $0/month, along with several subscription tiers at $20, $30, $40, $50, and $60/month. The page also mentions Monthly/Yearly billing, but does not state any annual discount. The configurations displayed across tiers appear largely the same, including 1GB storage, 1 project, 2 contributors, unlimited viewers, and team accounts, so the differences between plans are unclear. The copy mentions that users can purchase single-user access or a license for an entire organization, making it potentially suitable for individual pharmacovigilance analysts, small drug safety teams, or organizations that want to evaluate prebuilt reports quickly.

Pros and Cons

The main advantage is its clear vertical focus: the features are built around pharmacovigilance reporting, quarterly data, and sharing insights with colleagues. If the data is reliable, it could improve the efficiency of drug safety information retrieval. The drawbacks are also obvious: the page contains unrelated template content such as Happy Schedule, mockups, and the default ASP.NET About page, while the customer testimonials are also unrelated to pharmacovigilance, which hurts credibility. It also lacks information on data sources, compliance, payment methods, customer support channels, APIs, and integrations.

Access from China and Alternatives

There is no information in the main content about access from China, so its availability should be considered unknown for now. Payment methods are also not disclosed, so cross-border purchases would need further confirmation. For formal pharmacovigilance work, it is advisable to evaluate public FAERS/openFDA-related tools or established commercial drug safety analytics platforms in parallel, with particular attention to data sources, audit trails, export capabilities, and compliance support.